Back to top

oncology-screening: Archive

Zacks Equity Research

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change TARANo Net Change

Zacks Equity Research

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.

BMYPositive Net Change PFENegative Net Change REPLNegative Net Change ALLOPositive Net Change